Overview

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to characterize the pharmacokinetic profile of the two ATX-101 formulations.
Phase:
Phase 1
Details
Lead Sponsor:
Kythera Biopharmaceuticals